1.
Baldwin D.R., Honyebourne D., Wise R.Pulmonary disposition of antimicrobial agents:in vivo observations and clinical relevance // Antimicrob.Agents Chemother.v1992.v Vol.36.v P.1176 v1180.
2.
Bergogne Berezin E., Hamilton Miller J.M.T. Overview of spiramycin in respiratory tract infections // Drugs Investigation.v1993.v Vol.6, suppl.1.v P.52 v54.
3.
Bergogne Berezin E. New concepts in the pulmonary disposition of antibiotics // Pulmonary Pharmacology.v 1996.v Vol.8.vP.65 v81.
4.
Bergogne Berezin E. Spiramycin concentrations in the human respiratory tract:a review // J. Antimicrob. Chemother.v1988.vVol.22, suppl.B.v P.117 v122.
5.
Biermann C., Loken A., Riise R. Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice // J. Antimicrob. Chemother.v 1988.v Vol.22, suppl.B.v P.155 v158.
6.
Boezeman A.J., Kayser A.M., Siemelink R.J. Comparison of spiramycin and doxycycline in the empirical treatment of acute sinusitis: preliminary results // J. Antimicrob. Chemother.v1988.vVol.22, suppl.B.v P.165 v170.
7.
Carbon C.Clinical efficacy and place of spiramycin in the treatment of acute respiratory tract infections // Drugs Investigation.v 1993.v Vol.6, suppl.1.v P.35 v42.
8.
Davey P., Pechere J.vC., Speller D. Spiramycin reassessed // J. Antimicrob. Chemother.v1988.vVol.22, suppl.B.v Р.123 v126.
9.
De Cock L., Poels R. Comparison of spiramycin and erythromycin for low respiratory tract infections // J. Antimicrob. Chemother. v1988.v Vol.22, suppl.B.vP.159 v163.
10.
Denie C., Henrion J., Schmitz A., Heller F R Spiramycin induced cholestatic hepatitis // J. Hepatol. v1992.v Vol.16.v P.386.
11.
Descotes J. Chemical structure and safety of spiramycin // Drugs Investigation.v 1993.v Vol.6, suppl.1.v P 43 v48.
12.
Desnottes J.F., Diallo N., Moret G. Effects of spiramycin on adhesiveness and phagocytosis of gram positive cocci // J. Antimicrob. Chemother. v 1998.v Vol.22, suppl.B.vP.25 v32.
13.
Frydman A.M., Le Roux Y., Desnottes J.F.et al. Pharmacokinetics of spiramycin in man // J. Antimicrob. Chemother.v 1988.v Vol.22, suppl. B.v P.93 v103.
14.
Gendrel D., Bourrillon A., Bingen E. et al.Five day spiramycin versus seven day penicillin V in the treatment of streptococcal tonsillitis in children // Clin. Drug. Invest.v1997.v Vol.13.v P.338 v344.
15.
Jeannin L., Vergeret J., Caillaud D. et al.Community acquired pneumonia in healthy adults: 188 patients treated with spiramycin in private practice // Rev. Pneumologie Clin.v1992.v Vol.48.v P.263 v268.
16.
Kavi J., Webberley J.M., Andrews J.M., Wise R.A. A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin // J. Antimicrob. Chemother. v1988.vVol.22, suppl. B.vP.105 v110.
17.
Kernbaum S. Spiramycin - therapeutic value in humans // Semaine des Hopitaux de Paris.v1982.vVol.58.vP.289 v97.
18.
Kitzis M., Desnottes J.F., Brunel D. Spiramycin concentrations in lungtissue // J. Antimicrob. Chemother. v1988.vVol.22, suppl. B.vP.123 v126.
19.
Levrat M., Brette R., Truchot R. L-elimination biliaire des antibiotiques // Rev. Int .d-Hepatologie.v1964.vVol.14.v P.137 v169.
20.
Manolopoulos L., Adamopoulos C., Tzagourolakis A. et al. Spiramycin versus penicillin V in the empiric treatment of bacterial tonsillitis // Brit. J. Clin. Pract.v1989.vVol.43.v P.94 v96.
21.
Marrie T.J., Peeling R.W., Fine M.J. et al. Ambulatory patients with community acquired pneumonia: the friquency of atypical agants and clinical course // Amer. J. Med.v1996.v Vol.101.v P.508 v515.
22.
Pessayre D., Larrey D., Funck Brentano C., Benhamou J.P. Drug interactions and hepatitis induced by some macrolide antibiotics // J. Antimicrob. Chemother. v1985.vVol.16, suppl. A.v P.181 v194.
23.
Pilot M.A., Qin X.Y. Macrolides and gastrointestinal motility // J. Antimicrob. Chemother. v1988.vVol.22, suppl. B.v P.201 v206.
24.
Wise R. Clinical pharmacokinetics of spiramycin // Drugs Investigation.v 1993.v Vol.6, suppl. 1.vP.29 v34.